                </a></li></ul></div><p><strong>Figure 7.  <span>Effect of tumor EPOR-R129C expression on in vivo ERK1/2 phosphorylation, Ki67 proliferation antigen expression, microvessel density and hypoxia.</span></strong></p><a id="article1.body1.sec2.sec6.fig1.caption1.p1" name="article1.body1.sec2.sec6.fig1.caption1.p1"></a><p>Sections of pCR3.1 vector control and EPOR-R129C mammary fat pad tumors were analyzed by immunocytochemistry as described in <a href="#s4">Materials and Methods</a>. (A–C) Phospho-ERK, (D) Ki67, (E) CD31, and (F) Pimonidazole hypoxia marker. #P&lt;0.0001;*P = 0.0006; †P = 0.0008; § P = 0.026.</p>
